What is driving the growth of the Biosimilar Market?

The Biosimilar Market is expanding rapidly due to rising demand for affordable biologic therapies and the increasing prevalence of chronic and autoimmune diseases. As healthcare costs continue to surge globally, biosimilars are emerging as cost-effective alternatives to branded biologic drugs. India, being a global hub for biopharmaceutical manufacturing, plays a crucial role in supplying biosimilars both domestically and internationally.

Globally, the biosimilar market size was valued at USD 24.50 billion in 2024, and it is expected to grow at a CAGR of 17.60% during 2025–2034, reaching USD 123.95 billion by 2034. In India, this growth is driven by supportive government policies, strong R&D capabilities, and a robust pipeline of biosimilar products across therapeutic areas such as oncology, diabetes, and autoimmune disorders.

Overview of the Biosimilar Market

Biosimilars are biologic medical products that are highly similar to an already approved reference biologic in terms of structure, safety, and efficacy. They provide patients with more affordable treatment options for life-threatening diseases, including cancer, diabetes, rheumatoid arthritis, and growth hormone deficiencies.

India is one of the largest producers of biosimilars in the world, with companies like Biocon, Dr. Reddy’s Laboratories, and Intas Pharmaceuticals leading the charge. The country’s advanced biologics manufacturing infrastructure, coupled with regulatory frameworks aligned with global standards, positions India as a major biosimilar export hub.

Market Size and Share Analysis

The global biosimilar market reached USD 24.50 billion in 2024 and is expected to achieve USD 123.95 billion by 2034. India accounts for a substantial portion of this growth, owing to its cost-competitive production, skilled workforce, and expanding healthcare sector.

• Asia Pacific is emerging as a dominant biosimilar region due to rising healthcare expenditure and supportive biosimilar approval pathways.

• India, in particular, benefits from a large domestic patient pool, enabling faster clinical testing and market acceptance.

Market Dynamics and Trends

Key Market Drivers

• Rising burden of chronic diseases: Increasing prevalence of diabetes, cancer, and autoimmune disorders in India is boosting biosimilar demand.

• Government support and regulatory reforms: India’s regulatory framework for biosimilars, aligned with WHO and EMA guidelines, accelerates approvals and market entry.

• Patent expirations of blockbuster biologics: As major biologic patents expire globally, Indian firms have the opportunity to launch affordable biosimilar versions.

• Increased R&D investment: Indian biopharma companies are investing in advanced cell line development and bioprocessing technologies to enhance biosimilar production efficiency.

Request sample report: https://www.expertmarketresearch.com/reports/biosimilar-market/requestsample

Challenges

• High production costs compared to small-molecule drugs.

• Need for advanced analytical tools to ensure similarity in efficacy and safety.

• Stringent regulatory approval requirements and clinical testing costs.

Emerging Trends

• Growing adoption of monoclonal antibody biosimilars in oncology and autoimmune diseases.

• Expansion of domestic biosimilar clinical trials.

• Entry of global pharmaceutical giants into India through joint ventures and partnerships.

Market Growth Outlook

The biosimilar market is projected to grow robustly during the forecast period due to favorable government initiatives, expanding healthcare access, and local manufacturing incentives under programs like “Make in India” and PLI (Production Linked Incentive) schemes.

India’s biosimilar exports to Europe, Latin America, and Southeast Asia are also expected to rise significantly, driven by growing global acceptance of Indian biosimilars. With strong innovation, lower development costs, and a growing number of FDA and EMA-approved facilities, India is poised to be a key player in global biosimilar production.

Market Segmentation Analysis

By Product Type

• Recombinant Glycosylated Proteins

• Recombinant Non-Glycosylated Proteins

Recombinant glycosylated proteins, particularly monoclonal antibodies and erythropoietin, dominate the market due to their therapeutic applications in oncology and chronic diseases.

By Drug Class

• Insulin

• Recombinant Human Growth Hormone (rHGH)

• Granulocyte Colony-Stimulating Factor (G-CSF)

• Interferon

• Erythropoietin

• Etanercept

• Monoclonal Antibodies (mAbs)

• Follitropin

• Glucagon

• Calcitonin

• Teriparatide

• Enoxaparin Sodium

• Others

Among these, monoclonal antibodies and insulin biosimilars represent the largest market shares due to the rising prevalence of cancer and diabetes in India. Companies like Biocon and Dr. Reddy’s Laboratories have achieved regulatory approvals for several insulin and mAb biosimilars, strengthening India’s market presence.

By Indications

• Chronic Diseases

• Oncology

• Autoimmune Diseases

• Infectious Diseases

• Blood Disorders

• Growth Hormone Deficiency

• Others

The oncology segment holds a dominant share, driven by increasing cancer incidence and demand for cost-effective biologic therapies. The autoimmune disease segment is also expanding as biosimilars of adalimumab, infliximab, and etanercept gain traction in India.

By Procedure

• Invasive

• Non-Invasive

Non-invasive biosimilar treatments, particularly for diabetes and autoimmune diseases, are preferred due to improved patient compliance and reduced side effects.

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

The Asia Pacific region, with India as a central hub, is expected to register the fastest growth during 2025–2034 due to expanding biomanufacturing capabilities and favorable cost structures.

Market Opportunities and Challenges

Opportunities

• Patent expirations of major biologics like Humira, Avastin, and Herceptin open opportunities for biosimilar development.

• Rising medical tourism in India provides an export-driven growth avenue.

• Government support for biotech research and local clinical trial infrastructure.

• Expansion of domestic biopharmaceutical clusters in Hyderabad, Bengaluru, and Pune.

Challenges

• Complex manufacturing processes requiring high capital investment.

• Limited awareness among physicians and patients about biosimilars.

• Regulatory differences across countries affecting global market penetration.

Recent Developments

• Biocon Biologics partnered with Viatris to expand its biosimilar portfolio globally, including insulin and monoclonal antibodies.

• Dr. Reddy’s Laboratories launched Pegfilgrastim biosimilars in the U.S. and Europe, enhancing its international market presence.

• Samsung Bioepis and Amgen announced expansions in biosimilar production capacities in Asia and Europe.

• Pfizer and Boehringer Ingelheim continued to strengthen their global biosimilar portfolios, targeting oncology and autoimmune disease markets.

These developments underline the increasing investment in biosimilar innovation and India’s strategic role in global supply chains.

Competitor Analysis

The Biosimilar Market is highly competitive, with domestic and international players focusing on product diversification, pricing strategies, and R&D collaborations.

Key Companies Covered:

• Novartis AG

• Orion Pharma

• Pfizer Inc.

• Samsung Bioepis

• Coherus BioSciences, Inc.

• Amgen Inc.

• Eli Lilly and Company

• Takeda Pharmaceutical Company Limited

• Bristol-Myers Squibb Company

• Merck KGaA

• Teva Pharmaceutical Industries Ltd.

• Biocon

• Bayer AG

• AbbVie Inc.

• Allergan

• Dr. Reddy’s Laboratories Ltd.

• Boehringer Ingelheim International GmbH

• Biogen

Indian companies like Biocon, Dr. Reddy’s, and Intas are recognized globally for their cost-effective, high-quality biosimilars, while global firms are partnering with Indian manufacturers to expand regional footprints.

Frequently Asked Questions (FAQs)

Q1. What is the current size of the India Biosimilar Market?
The India biosimilar market contributes significantly to the global biosimilar market, which was valued at USD 24.50 billion in 2024 and is expected to reach USD 123.95 billion by 2034.

Q2. What are the key factors driving the growth of the India Biosimilar Market?
Rising chronic disease burden, patent expirations of biologics, government support, and the cost-effectiveness of biosimilars are major growth drivers.

Q3. Which drug classes dominate the India biosimilar market?
Monoclonal antibodies, insulin, and erythropoietin dominate due to their broad therapeutic applications and high clinical demand.

Q4. Who are the leading players in the global biosimilar market?
Major players include Biocon, Novartis, Pfizer, Amgen, Dr. Reddy’s Laboratories, and Samsung Bioepis.

Q5. What is the growth outlook for India’s biosimilar industry by 2034?
With advancements in biologic R&D, supportive policies, and export potential, India’s biosimilar market is projected to witness robust double-digit growth through 2034.